Dr. Pete Smith is an entrepreneur at MPM and BioImpact Capital, an affiliate manager of MPM. Currently, he is serving as the CSO of a newly formed stealth portfolio company.
Dr. Smith has over 30 years of industry experience and is a proven leader in early drug discovery and development, having held key senior roles at Alnylam Pharmaceuticals, Moderna Therapeutics and Millennium Pharmaceuticals. Prior to joining MPM and BioImpact Capital, Pete was Chief Early Development Officer at Alnylam Pharmaceuticals with a focus on RNAi-based medicines in four therapeutic areas including genetic medicines, cardio-metabolic diseases, infectious diseases, central nervous system diseases and ocular diseases. Prior to Alnylam, Pete was SVP and Head of R&D Non-Clinical at Moderna and served as Co-Head of R&D at Millennium where he worked for 13 years. He has extensive experience in drug discovery and development across multiple therapeutic areas including oncology, inflammation and infectious disease, as well as technologies including new modalities such as mRNA and siRNA. During his career, Pete has overseen the development of multiple therapeutics, such as Celebrex™, Inspra™, Velcade™, Entyvio™, Onpattro™, Givlarri™, Oxlumo™ and Vutrisiran. Pete began his career with 17 years in industry at SmithKline, Merck, Searle/Monsanto and Pharmacia in roles of increasing responsibility.
Dr. Smith earned a Ph.D. in pharmacology and toxicology from the University of Arizona, and a B.S. from Fairfield University.